Dettagli per singolo studio

DEC-NET Serial number GB408

Published online	24/05/2005 17.21.00
Last updated	01/08/2005 13.07.47


This trial has been approved by an ethics committee
Current trial status	Open (actively recruiting new participants)
Target N. of subjects	N/A
Major Disease (ICD9 class)	Contact dermatitis and other eczema
Experimental drug
Derma Cal Plus, herbal skin cream Treatment regimen (dosage and duration) Topical application
Gender	Both
Age (range)	2 months to 5 years
Eligibility criteria
Inclusion criteria
Children with mild or moderate atopic eczema within the past month Children whose parents give informed consent
Exclusion criteria
Children whose parents refuse consent Children with no recent history of a flair up of atopic eczema
Trial design/methodology
Phase	2
Kind of study	Efficacy Bioequivalence
Design	Controlled Randomised Blinded Double blind
Purpose of study
A double blind randomised placebo controlled trial to examine the effectiveness of 'Derma Cal Plus cream' in the treatment of children with mild to moderate atopic eczema.
Primary outcomes
Reduction in severity of atopic eczema and reduction of frequency of flair ups as reported by parents in questionnaire
Secondary outcomes
Reduction in signs and symptoms of atopic eczema, such as reduced discomfort, reduced stratching etc as reported by parents during monthly questionaire.
Summary of study design, objectives, and ongoing research findings
A double blind randomized placebo controlled trial to investigate the therapeutic properties of Derma Cal Plus, a herbal skin cream, in the treatment of eczema